These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 33826784)

  • 21. SARS CoV-2 vaccine AND rituximab. Comment on: "SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response" by Verhoeven Joint Bone Spine. 2021;88:105258.
    Mungmunpuntipantip R; Wiwanitkit V
    Joint Bone Spine; 2022 Jan; 89(1):105281. PubMed ID: 34600149
    [No Abstract]   [Full Text] [Related]  

  • 22. Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines.
    Nascimento Júnior JAC; Santos AM; Cavalcante RCM; Quintans-Júnior LJ; Walker CIB; Borges LP; Frank LA; Serafini MR
    Drug Dev Ind Pharm; 2021 Apr; 47(4):673-684. PubMed ID: 33826439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 (COVID-19) Vaccine Development and Production: An Ethical Way Forward.
    Iserson KV
    Camb Q Healthc Ethics; 2021 Jan; 30(1):59-68. PubMed ID: 32498742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.
    Sharma D
    Expert Rev Vaccines; 2021 Sep; 20(9):1051-1057. PubMed ID: 34313516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2: Unique Challenges of the Virus and Vaccines.
    Mahmoodpoor A; Sanaie S; Samadi P; Yousefi M; Nader ND
    Immunol Invest; 2021 Oct; 50(7):802-809. PubMed ID: 34109900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Problematic Covid-19 vaccine trials in times of vaccine nationalism.
    Ravinetto R
    Indian J Med Ethics; 2021; VI(2):1-7. PubMed ID: 33908359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The discussion of related issues in the efficacy evaluation of COVID-19 vaccine].
    Jiang ZW; Xia JL
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jan; 56(1):82-86. PubMed ID: 35092996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
    JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
    Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY
    Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical trials and the COVID-19 pandemic.
    Retsas S
    Hell J Nucl Med; 2020; 23(1):4-5. PubMed ID: 32361715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvantation helps to optimise COVID-19 vaccine candidate.
    Li JX; Zhu FC
    Lancet Infect Dis; 2021 Jul; 21(7):891-893. PubMed ID: 33705726
    [No Abstract]   [Full Text] [Related]  

  • 32. Moving towards more patient-centred clinical trials in IBD.
    Noor NM; Parkes M; Raine T
    Nat Rev Gastroenterol Hepatol; 2021 Oct; 18(10):673-674. PubMed ID: 34312526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Equipoise in Clinical Trials: Enough Uncertainty in Whose Opinion?
    Alexander JH
    Circulation; 2022 Mar; 145(13):943-945. PubMed ID: 35344405
    [No Abstract]   [Full Text] [Related]  

  • 34. COVID-19, equipoise and observational studies: a reminder of forgotten issues.
    Yusuf E; Maiwald M
    Infection; 2021 Apr; 49(2):371-373. PubMed ID: 32588335
    [No Abstract]   [Full Text] [Related]  

  • 35. Understanding Equipoise.
    Hoffer LJ
    Nutr Clin Pract; 2020 Jun; 35(3):495-498. PubMed ID: 32347586
    [No Abstract]   [Full Text] [Related]  

  • 36. Dual Uncertainties: On Equipoise, Sex Differences and Chirality in Clinical Research.
    Dahlen S
    New Bioeth; 2021 Sep; 27(3):219-229. PubMed ID: 33944708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proportionality, wrongs and equipoise for natural immunity exemptions: response to commentators.
    Pugh J; Savulescu J; Brown RC; Wilkinson D
    J Med Ethics; 2022 Nov; 48(11):881-883. PubMed ID: 35927021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What's a Hospital to Do? Equipoise, Pandemics and Single-site Clinical Trials.
    Seto TB
    Narrat Inq Bioeth; 2021; 11(1):24-26. PubMed ID: 34334461
    [No Abstract]   [Full Text] [Related]  

  • 39. An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times.
    García-Montero C; Fraile-Martínez O; Bravo C; Torres-Carranza D; Sanchez-Trujillo L; Gómez-Lahoz AM; Guijarro LG; García-Honduvilla N; Asúnsolo A; Bujan J; Monserrat J; Serrano E; Álvarez-Mon M; De León-Luis JA; Álvarez-Mon MA; Ortega MA
    Vaccines (Basel); 2021 Apr; 9(5):. PubMed ID: 33925526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Being fair to participants in placebo-controlled COVID-19 vaccine trials.
    Dal-Ré R; Orenstein W; Caplan AL
    Nat Med; 2021 Jun; 27(6):938. PubMed ID: 33903751
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.